作者
Jun Liang,Michael J. Lambrecht,Teresita L. Arenzana,Samuel Aubert‐Nicol,Linda Bao,Fabio Broccatelli,Jianping Cai,Céline Eidenschenk,Christine Everett,Tom A. Garner,Felix Gruber,Pouyan Haghshenas,Malcolm P. Huestis,Peter Hsu,Ponien Kou,Araz Jakalian,Robin Larouche‐Gauthier,Jean‐Philippe Leclerc,Denis H. Y. Leung,Aaron J. Martin,Jeremy Murray,Madeleine Prangley,Sascha Rutz,Satoko Kakiuchi-Kiyota,Alexander L. Satz,Nicholas J. Skelton,Micah Steffek,Daniel Stoffler,Jawahar Sudhamsu,Sophia Tan,Jian Wang,Shouliang Wang,Qiuyue Wang,Timothy J. Wendorff,Moreno Wichert,Arun A. Yadav,Christine Yu,Xiaojing Wang
摘要
We were attracted to the therapeutic potential of inhibiting Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b), a RING E3 ligase that plays a critical role in regulating the activation of T cells. However, given that only protein-protein interactions were involved, it was unclear whether inhibition by a small molecule would be a viable approach. After screening an ∼6 billion member DNA-encoded library (DEL) using activated Cbl-b, we identified compound